Pieris Pharmaceuticals Inc
PIRS
Market Cap$17.96M
Close$
Share Statistics
| Market cap | $17.96 Million |
|---|---|
| Enterprise Value | $-52,477,736.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.83 |
| Beta | 0.66 |
| Outstanding Shares | 11,052,741 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.65 |
|---|---|
| PEG | -3.45 |
| Price to Sales | -13.6 |
| Price to Book Ratio | 3.4 |
| Enterprise Value to Revenue | 990.15 |
| Enterprise Value to EBIT | 4.03 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...